<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.channelnewsasia.com/news/world/astrazeneca-s-imfinzi-gets-fda-priority-review-for-small-cell-lung-cancer-12137914?utm_source=dlvr.it&amp;utm_medium=twitter"/>
    <meta property="og:site_name" content="CNA"/>
    <meta property="article:published_time" content="2019-11-29T15:27:00+00:00"/>
    <meta property="og:title" content="AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer"/>
    <meta property="og:description" content="British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration ..."/>
  </head>
  <body>
    <article>
      <h1>AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer</h1>
      <address>
        <time datetime="2019-11-29T15:27:00+00:00">29 Nov 2019, 15:27</time>
      </address>
      <p>British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.</p>
      <p>REUTERS: British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.</p>
      <p>The company said the FDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.</p>
      <aside>Advertisement</aside>
      <aside>Advertisement</aside>
      <p>A final decision is expected in the first quarter of 2020.</p>
      <p>(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)</p>
      <footer>Source: Reuters</footer>
    </article>
  </body>
</html>